公开(公告)号：US11718672B2

公开(公告)日：2023-08-08

申请号：US17670917

申请日：2022-02-14

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Tomoyuki Igawa ,  Shu Wen Samantha Ho

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2809 ,  C07K16/28 ,  C07K16/2878 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

摘要： The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

公开(公告)号：US20210301016A1

公开(公告)日：2021-09-30

申请号：US17216981

申请日：2021-03-30

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Tomoyuki Igawa ,  Shu Wen Samantha Ho

IPC分类号： C07K16/28

摘要： The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

公开(公告)号：US20220251201A1

公开(公告)日：2022-08-11

申请号：US17670917

申请日：2022-02-14

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Tomoyuki Igawa ,  Shu Wen Samantha Ho

IPC分类号： C07K16/28

摘要： The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

公开(公告)号：US11274151B2

公开(公告)日：2022-03-15

申请号：US17216981

申请日：2021-03-30

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Tomoyuki Igawa ,  Shu Wen Samantha Ho

IPC分类号： C07K16/28 ,  A61K39/00

摘要： The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

公开(公告)号：US20240010725A1

公开(公告)日：2024-01-11

申请号：US18343850

申请日：2023-06-29

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Tomoyuki Igawa ,  Shu Wen Samantha Ho

IPC分类号： C07K16/28

CPC分类号： C07K16/2809 ,  C07K16/28 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2039/505

摘要： The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

公开(公告)号：US20230147840A1

公开(公告)日：2023-05-11

申请号：US17914855

申请日：2021-03-30

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Sotaro Naoi ,  Shu Feng ,  Siok Wan Gan

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2809 ,  C07K16/2878 ,  C07K16/303 ,  A61K2039/507

摘要： An antigen-binding molecule comprising a first antigen-binding moiety that is capable of binding to CD3 and CD137 (4-1BB), but does not bind to CD3 and CD137 at the same time (i.e. dual-binding to CD3 and CD137 but not simultaneously); and a second antigen-binding moiety capable of binding to a molecule specifically expressed in a cancer tissue, specifically Glypican-3 (GPC3) is provided. Due to the dual binding to CD3 and CD137 but not simultaneously and with fine-tuned binding kinetics, and the binding to GPC3, the multispecific antigen-binding molecule express strong cytotoxic activity for cancer cells with reduced adverse effects. Further, by adapting antibody engineering technologies and a molecular format design (including charged mutations in the framework region and/or constant region, VH/VL exchanged, and Fc region selection), the multispecific antigen-binding molecule with favorable stability, manufacturability/producibility and structural homogeneity is provided.